It has become evident that many human disorders are characterised by mitochondrial dysfunction either at a primary level, due to mutations in genes whose encoded products are involved in oxidative phosphorylation, or at a secondary level, due to the accumulation of mitochondrial DNA (mtDNA) mutations. This has prompted keen interest in the development of cell and animal models and in exploring innovative therapeutic strategies to modulate the mitochondrial deficiencies observed in these diseases. Key advances in these areas are outlined in this review, with a focus on Leber hereditary optic neuropathy (LHON). This exciting field is set to grow exponentially and yield many candidate therapies to treat this class of disease.
Mitochondrial dysfunction in human disorders
The mitochondrion, an intracellular organelle believed to have originated from an aerobic bacterium some 1.5 billion years ago [1] , provides an essential supply of cellular energy in the form of ATP generated via oxidative phosphorylation (OXPHOS) with hundreds of mitochondria populating the cytoplasmic compartment [2] (Figure 1 ). Given the essential role of these organelles in cellular bioenergetics, it is not surprising that mitochondrial dysfunction is a hallmark of many heritable and acquired disorders. The advent of genetic linkage and next-generation sequencing (NGS) technologies has led to significant insights into the role of mitochondrial mutations in driving disease processes [3, 4] . Mitochondrial disorders can be subdivided into three classes: (i) primary mitochondrial disorders caused by mutations in mitochondrial genes; (ii) disorders with mutations in nuclear genes involved in mitochondrial function; and (iii) secondary disorders that arise from the accumulation of mitochondrial damage over time frequently involving neurodegenerative pathologies [5] [6] [7] [8] . Tissues such as retina, brain, and muscle, which have enormous energy requirements, are particularly vulnerable to variations in mitochondrial function. Approximately 50% of mitochondrial disorders have an ocular phenotype [9] . In addition to dominant optic atrophy (DOA) [10] and LHON (Box 1 [11] ), mitochondrial dysfunction has been linked to multifactorial diseases, including age-related macular degeneration (AMD) [7, 12] and diabetic retinopathies [12] , as well as complex disorders involving multiple tissues, including the eye, such as neuropathy, ataxia and retinitis pigmentosa (NARP) and Kearns-Sayre syndrome (KSS) [13, 14] .
The significant mitochondrial dysfunction characteristic of many disorders has galvanised interest in the development of methodologies to simulate mitochondrial disorders in animal models and to deliver gene and small molecule-based drugs to the mitochondria. Studies in animal models will be essential in the development of therapies for these diverse and frequently devastating clinical conditions. Here, we review recent work highlighting the role of mitochondrial dysfunction in disease and the progress made towards understanding and treating these diseases, with a particular focus on LHON, a genetically wellcharacterised primary mitochondrial disorder.
Molecular characteristics of mitochondrial dysfunction
Screens for pathogenic mtDNA mutations initially focused on genes encoding components of OXPHOS, such as those implicated in complex I deficiency disorders [15] , together with nuclear genes whose products participate in OXPHOS. Additionally, pathogenic mutations have been found in genes whose products facilitate translation and assembly of OXPHOS complexes, in genes implicated in the fission and fusion of these dynamic organelles, and in mtDNA maintenance [16] . Mutations can operate through quantitative effects on mtDNA numbers or qualitative effects on mtDNA function. Mutations in the nuclear-encoded mitochondrial-specific DNA polymerase g (POLG) involved in mtDNA replication and maintenance [17] have been implicated in diverse neurodegenerative conditions, including mitochondrial recessive ataxic syndrome (MIRAS) and late-onset chronic progressive ophthalmoplegia [18] . Factors that modulate mitochondrial RNA (mtRNA) metabolism by influencing mtRNA production, processing, stability, and polyadenylation have also been implicated. Mutations in mitochondrial amino acyl-tRNA synthetases (mt-aaRSs), key players in the translational machinery that link amino acids to their cognate mitochondrial tRNAs, are involved in several disorders [19] . Mutations in specific mitochondrial tRNAs have been reported [20, 21] ; for example, position 3243 in the mitochondrial tRNA Many nuclear genes implicated in mitochondrial disease are inherited in an autosomal or X-linked recessive fashion, although dominant inheritance also occurs. By contrast, mutations in mtDNA are inherited maternally and involve hundreds or thousands of mitochondria within each cell, with multiple mtDNA genomes in every mitochondrion. Interindividual and intertissue variations in levels of heteroplasmy (ratio of mutant:wild type mtDNA) can greatly influence the severity of many mitochondrial diseases, including LHON [22] . Mitochondrial disorders are subject to many other factors that can influence the phenotype, including environmental modifiers; risk factors for LHON include smoking, solvent exposure, and antiretroviral medication [23] [24] [25] . Genetic modifiers may also impact on disease phenotype [26, 27] ; for example, an X-linked modifier locus for LHON has been reported [26] . Furthermore, certain mitochondrial backgrounds may modulate susceptibility to disease and this may be linked to variations in oxygen consumption, efficiency of electron transport, ATP generation, and reactive oxygen species (ROS) production [28] . Evidence suggests that for multifactorial disorders, such as AMD and Parkinson's disease (PD), specific mitochondrial haplogroups can aggravate or attenuate disease risk [29] [30] [31] [32] [33] . Evidence in support of mitochondrial haplogroups modulating disease is more compelling for disorders such as LHON and AMD than for PD and Huntington disease (HD), where equivocal findings have been reported.
Although great diversity exists in the nuclear and mtDNA mutations causative of mitochondrial diseases, at times there is a perturbation of common pathways, including ROS production, ATP synthesis, calcium homeostasis, regulation of the permeability transition pore (PTP), and mitochondrial biogenesis, suggesting the possibility of developing common therapies for these conditions [5, 6] . Although it is well established that somatic mtDNA mutations accumulate and mitochondrial function attenuates in ageing animals, the relative impact of ROS production, OXPHOS capacity, mtDNA replication errors, and mitochondrial biogenesis remains ill defined [34] . Indeed, there is some debate regarding the free radical theory of ageing, which purports that reduced OXPHOS capacity results in increased ROS levels, causing mtDNA mutation and thereby exacerbating reductions in OXPHOS capacity. For example, mutator mice (with a knock-in mtDNA polymerase gamma mutation [35] ) (Table 1 ) have no or marginal increases in ROS production despite compromised OXPHOS capacity [34, 36] . In exploring these complex interactions and determining the cellular consequences of mitochondrial mutations, cellular and animal models offer a powerful resource.
Cellular models of mitochondrial disease
Manipulation of the mitochondrial genome requires circumventing substantial barriers, including delivery to the thousands of mitochondrial genomes in a cell and transfer across the double membrane of the mitochondrion. Recapitulation of mitochondrial disorders in cell culture has largely relied on cytoplasmic hybrid cells or cybrids, in which the mitochondrial content of a host cell has been manipulated such that endogenous mtDNA has been depleted and repopulated with donor mtDNA from platelets or enucleated cells [37, 38] . Cybrids have been used to characterise the disturbances in cellular bioenergetics LHON is caused by mutations in genes encoding components of the mitochondrial respiratory NADH-ubiquinone oxidoreductase complex (complex I). Seven of the 46 subunits of mammalian complex I are encoded by the mitochondrial genome (ND1-6 and ND4L). Mutations in three subunits, G3460A in ND1, G11778A in ND4 and T14484C in ND6, account for most LHON cases. LHON demonstrates many of the features of mitochondrial inheritance discussed in this review, with disease severity influenced by levels of heteroplasmy, mitochondrial haplogroups, nuclear modifier loci, and environmental factors. For example, the G11778A (ND4) and T14484C (ND6) LHON mutations on subgroups of a mitochondrial haplogroup J or the G3460A (ND1) mutation on the mitochondrial haplotype K background have been associated with increased risk of visual loss [29] . Differences between haplogroups may be partially due to mtDNA quantity, which influences OXPHOS capacity [30] and may account for gender differences in disease penetrance in LHON; there is a suggestion that oestrogens increase mtDNA levels, enhancing oxygen consumption and ATP generation [87] . associated with specific mitochondrial mutations. Examples include a partial tandem duplication of tRNA PHE in late-onset mitochondrial myopathy [39] , causative of reduced oxygen consumption rates in cybrids, and the A3243G transition in the tRNA LEU(UUR) gene, which results in defects in respiratory chain assembly and activity, causative of MELAS, deafness, and cardiomyopathy [40] . The approach has also been adopted to evaluate the relative contribution of mitochondrial and nuclear genetic backgrounds in driving disease risk. Although cybrids represent valuable cellular models for experimentation, they do not recapitulate many of the multivalent features of disease in whole organisms. Moreover, studies typically have been limited to analyses using single cybrid cell lines, at times using cell types not directly relevant to the disease pathology, thereby mirroring only some aspects of disorders that frequently involve multiple cell types.
Cybrid and stem cell technologies have been combined to explore mitochondrial dysfunction in neurons differentiated from mouse embryonic stem (ES) cell cybrids carrying complex I and complex IV mutations, thereby generating cell types directly relevant to a condition with mitochondrial mutations [41] . Recently, depletion of endogenous mtDNA in human pluripotent stem cell-derived neural progenitors (hNPs) using dideoxycytidine and replacement with mutant mtDNA carrying the G11778A NADH dehydrogenase 4 (ND4) LHON mutation, together with delivery of donor mtDNA to hNP cybrids, was reported [42] .
Other cell types have been utilised to generate cellular models of mitochondrial disease, including primary cells such as fibroblasts from skin biopsies [43, 44] or induced pluripotent stem (iPS) cells, thereby recapitulating mitochondrial disorders in patient-derived cells [45] . Although there are many applications for iPS cells, which are stem cells that have undergone exogenously directed reprogramming from nonpluripotent cells and that can subsequently be differentiated into cell types relevant to particular disease pathologies, limitations with the technology are evident. Significant variance has been observed between the behaviour of individual iPS clones and subclones after reprogramming, genetic and epigenetic differences between iPS-derived clones compared with endogenous cell types have been found, and, as with any cell model, the multifaceted nature of disease cannot be fully simulated. Various disorders addressed using primary cells and iPS methodologies include HD, PD, and Alzheimer's disease (AD), all of which involve significant mitochondrial dysfunction in cells [46] . Despite these drawbacks, cybrids and iPS technologies have revolutionised the generation of cell models of disease, providing insights into disease pathogenesis and offering in vitro systems to screen candidate therapies [47] . Advances in methodologies to differentiate stem cells into homogeneous populations of specific cell lineages will improve the resolution of cell models and, therefore, their future utility to expedite elucidation of disease processes and to evaluate therapies. However, animal models of mitochondrial disease will remain invaluable for elucidating disease mechanisms and essential for preclinical evaluation of therapies.
Animal models of mitochondrial disease Methodologies adopted to generate animal models include nuclear transgenesis of genes involved in OXPHOS and mtDNA maintenance, allotopic expression of mitochondrial genes, chemically induced models, and transmitochondrial approaches (Table 1 ) [47] . For disorders where the pathogenesis originates from mutations in nuclear genes whose encoded products participate in OXPHOS, standard methodologies for nuclear transgenesis can be used. A recent example is a transgenic model of Leigh syndrome, which is caused by mutations in the gene encoding NADH dehydrogenase (ubiquinone) iron-sulfur protein 4 (NDUFS4), a nuclear-encoded complex I subunit [48] . Transgenic mice with a conditional knockout of the NDUFS4 gene presented with a fatal progressive encephalopathy similar to human patients, regardless of whether the knockout was global or exclusive to the central nervous system (CNS), suggesting that NDUFS4 function is of particular relevance to the CNS. Although generating animal models mutant for nuclear-encoded components of OXPHOS is feasible, few models exist thus far [47, 49, 50] ( Table 1) . Given the conserved nature of many OXPHOS components, in many cases conditional models will be required to overcome embryonic lethality associated with global mutants. Nuclear transgenesis has been used to generate mice with elevated rates of mitochondrial mutation due to mutations in the polymerase gamma A (PolgA) gene [35, 50] encoding the nuclear subunit of mtDNA polymerase and involved in proofreading activity in mtDNA. Mutator mice simulate mtDNA genotypes and phenotypes seen in aged animals [35, 50] . Deletor mice with higher rates of mtDNA mutation have been generated with mutations in Twinkle, which was recently shown to be the only helicase involved in mtDNA replication in mammalian mitochondria [51] .
Modelling mtDNA mutations in animals presents greater challenges than does nuclear transgenesis, impeded by the multitude of mitochondrial genomes in a cell, the double membranes of the mitochondria, and selective pressures against mtDNAs that compromise OXPHOS. A method to circumvent such barriers has been allotopic expression in the nuclear compartment of a mitochondrial gene engineered with mitochondrial targeting sequences (MTS) facilitating protein import to mitochondria (Table  1) . Such an approach has been applied in the generation of transgenic mice expressing wild type or L156R mutant forms of the mitochondrial ATP synthase 6 (ATP6) gene implicated in neuropathy, ataxia, and retinitis pigmentosa (NARP) and maternally inherited Leigh syndrome (MILS) [52] . With regard to LHON, intravitreal injection of plasmid DNA followed by electroporation [53] or an adenoassociated virus (AAV) [54] expressing a human ND4 complex I R340H mutant recapitulated features of human LHON, including retinal ganglion cell (RGC) and optic nerve degeneration; both studies used allotopic expression of ND4 but differing modes of delivery.
An alternative approach for the production of animal models has involved manipulation of mtDNA in ES cells. For example, xenomitochondrial mice with divergent nuclear and mtDNA backgrounds have been generated by injecting cybrid 129S6 ES cells containing Mus terricolor mtDNA into Mus musculus domesticus (C57BL) blastocysts. Backcrossing to C57BL mice for ten generations produced mice with a homogeneous nuclear background and divergent nuclear and mtDNA genomes [55] . As with animal models of nuclear disorders, simulating mitochondrial disorders in animals does not always result in a disease phenotype. Although preliminary studies with cybrid cells demonstrated mitochondrial dysfunction, xenomitochondrial mice exhibited no phenotype, suggesting compensatory mechanisms at play [55] . Although the process of mitochondrial depletion can result in cellular damage, transmitochondrial mice have been generated by fusion of cytoplasts containing mutant mtDNA with mitochondria-depleted mouse ES cells or by electrofusion of cytoplasts into mouse zygotes. These so-called 'mito-mice' carrying a mtDNA deletion encompassing 6tRNA and seven structural genes, a mutation in the genes encoding cytochrome oxidase I (COI) or NADH dehydrogenase 4 (ND6) have been generated [56] . Recently, using a homoplasmic G14600A ND6 mutant cell line, cybrids from this cell line were fused with ES cells depleted of mtDNA to generate a mouse with a mitochondrial mutation in ND6 [57] that recapitulates many features of LHON. The model suggests that LHON is due to oxidative stress rather than to ATP deficiency, because in this model, no reduction in ATP production was evident. Improved methods for mitochondrial transgenesis will aid animal model generation. Targeting of genetic modifications to specific cell lineages greatly increased the resolution of nuclear transgenic technologies and, likewise, tissue-specific manipulation of mtDNA would enhance the variety of models available for mitochondrial disorders. Development of potent methods for DNA delivery to mitochondria will find broad utility in the future generation of transgenic animals and in exploring novel therapies for mitochondrial disorders. Delivering molecules to mitochondria Although an array of methods has been explored to achieve delivery of nucleotides and peptides to mitochondria [58] [59] [60] [61] , few data exist on the relative efficiencies of methodologies, levels of delivery to cytoplasm versus subcellular targets, proportions of mitochondria targeted, and longevity of delivered molecules. Nevertheless, delivery technologies under development are detailed below and provide an overview of the various approaches being considered. Biolistic methods enable DNA transfer to mitochondria using heavy particles coated with DNA; however, successful delivery has been limited to simple organisms, such as the yeast Saccharomyces cerevisiae [60] . Other strategies for delivery use nanocarriers, such as MITO-Porter, a liposome-based vector used for delivery to the mitochondrial matrix, in a process involving membrane fusion [62] ; inclusion of a mitochondrial targeting signal (MTS) peptide with MITO-Porter enhanced mitochondrial delivery [63] . Liposome-like carriers derived from dequalinium (DQAsomes) have been used to deliver a minimitochondrial genome with a GFP gene into the mitochondrial compartment of macrophage cells using GFP fluorescence to monitor delivery [64] . The lipophilic cation triphenylphosphonium (TTP) has been used extensively to deliver nucleotide, peptide, and chemical molecules facilitated by the large mitochondrial plasma membrane potential (negative inside mitochondria), driving accumulation of this positively charged carrier within mitochondria. The approach was used to deliver the antioxidant MitoQ in animal models, prompting its evaluation in clinical studies [65, 66] . Peptides, including mitochondrial-penetrating and Szeto-Schiller peptides, have been tested for their ability to direct delivery to mitochondria [6] . Indeed, water-soluble Szeto-Schiller peptides, which target the inner mitochondrial membrane (IMM), have antioxidant properties themselves, and are in preclinical and clinical development for several indications [67] . The recombinant human mitochondrial transcription factor A protein (TFAM), which itself stimulates mitochondrial biogenesis, has been used to deliver mtDNA to mitochondria, a strategy termed 'protofection'. Wild type mtDNA was delivered to near homoplasmic mutant mtDNA cybrid lines generated using platelets from patients with LHON or PD and primary fibroblasts from a patient with Leigh syndrome [44, 68] , resulting in significant improvements in mitochondrial respiration, biogenesis, and transcription in treated cells.
An alternative strategy to compensate for mitochondrial dysfunction involves delivery of polycistronic RNAs (pcRNAs) encoding parts of the mitochondrial genome [69] . General use of modified mRNAs is being considered as an alternative to delivery of double-stranded DNA to minimise immunostimulatory effects [70] , a potential advantage of mitochondrial pcRNA delivery. A protozoanderived mitochondrial tRNA carrier complex has been used to facilitate mitochondrial delivery of pcRNAs in vivo in old rodents to increase the respiratory capacity of skeletal muscles, which typically decreases with age [69] . Furthermore, recent insights into the mammalian mtRNA transcriptome have demonstrated the presence of greater numbers of nuclear-encoded RNAs than previously envisaged, including tRNAs, miRNAs, and rRNA [71] , revealing RNA import pathways for RNA delivery to mitochondria. For example, a 20-nucleotide stem-loop sequence from the RNA component of the RNAse P enzyme (H1) imported into mitochondria has been used to facilitate transfer of nuclear RNAs, both tRNAs and mRNAs, to mitochondria, an important observation in the field [72] . Knowledge gained from transcriptomics will expedite the development of additional methods for targeting nucleotide delivery to mitochondria, methodologies that will be applied in the future exploration of therapies for mitochondrial disorders. The exploitation of endogenous import mechanisms will likely provide strategies that target sufficient proportions of intracellular mitochondria to elicit readily quantifiable and potentially beneficial effects. Murine model for Leigh syndrome Gene replacement NDUFS4 AAV2/1 stereotactic injection in mediolateral vestibular nucleus [105] Murine model for ethylmalonic encephalopathy Gene replacement to liver ETHE1 AAV2/8-mediated gene transfer to liver [75] Harlequin mice with complex I deficiency-related neurodegeneration Gene replacement AIF1 AAV2/2 intravitreal injection followed by electroporation [106] Two murine models for LHON Allotopic gene replacement ND4 AAV2/2 and electroporation in vitreous [53, 54] MTPT model for PD Trans-kingdom gene replacement Candidate gene therapies for mitochondrial disorders Nucleotide delivery methodologies, together with methods to optimise protein import into mitochondria, are being used to explore candidate therapies for mitochondrial deficiency disorders ( Table 2) . Most of the mitochondrial proteome (comprising approximately 1500 polypeptides)
originates from proteins expressed from nuclear genes with signals (MTS) to facilitate import into mitochondria. This feature has been leveraged successfully in gene therapies for mitochondrial disorders and was first demonstrated decades ago in studies of ornithine transcarbamylase (OTC) deficiency, a urea cycle disorder. By using
More than 300 geneƟc diseases can be passed from mother to child because of mutated genes. Researchers at Oregon Health & Science University have developed a form of gene therapy to prevent these diseases.
Gene therapy to prevent diseases passed from mother to child
The mitochondria
Mitochondria are the powerstaƟons of a cell, providing it with the energy to funcƟon. A mother's egg cell contains thousands of mitochondria, each containing its own DNA. If defecƟve, the DNA in these cells can pass diseases from mother to child. Here's how researchers hope to use gene therapy to prevent these diseases:
The cell nucleus holds chromosomes, which contain more than 99 percent of a person's DNA. The nucleus is removed from the mother's egg cell.
The nucleus is also removed from an egg cell provided by a donor.
The nucleus removed from the mother's egg cell is inserted into the donor egg cell. Thus, the donor's normal mitochondria replaces the mother's defecƟve mitochondria containing mutated DNA.
A sperm cell is injected to ferƟlize the egg. The cell is then re-implanted into the mother and develops into a healthy baby. Mother's nucleus removed Figure 2 . Diagrammatic representation of germline gene therapy for human mitochondrial disorders. There is growing interest in developing methodologies to circumvent the inheritance of mitochondrial disorders in the offspring of an affected parent by using a strategy involving the use of genetic material from three individuals: the mother, the father, and a donor female. In essence, the approach involves using an enucleated egg from a donor female into which the nucleus from the mother's egg is inserted, followed by fertilisation by the father's sperm of the 'hybrid' egg, whose mtDNA material originates from the donor female and nuclear material from the mother. Significant strides have been made recently towards this objective [83] [84] [85] [86] . Reproduced with kind permission from Shoukhrat Mitalipov, Oregon Health & Science University.
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the endogenous MTS, a nuclear-encoded wild type gene carried by adenovirus was delivered to mitochondria in an OTC-deficient mouse, resulting in correction of the defect [73] ; recently, an AAV, the AAV2/8 serotype, has also been used for OTC gene therapy in rodents [74] . More recently, a similar approach exploiting mitochondrial import and an AAV2/8 vector was used in liver to treat mice with ethylmalonic encephalopathy, a fatal recessive disorder caused by mutations in the ethylmalonic encephalopathy 1 (ETHE1) nuclear gene encoding a mitochondrial sulfur dioxygenase involved in detoxifying hydrogen sulfide [75] . Allotopic expression of modified mitochondrial genes to facilitate nuclear expression and subsequent protein import into mitochondria overcomes the barrier of mitochondrial polyploidy and, hence, is also being used for therapeutic development. As with any gene therapy, the efficacy and longevity of the treatment will in part depend on the vector used for gene delivery. For example, DNA electroporation or AAV-mediated delivery into retinal ganglion cells of a wild type ND4 complex I subunit incorporating a MTS prevented RGC loss and optic nerve degeneration in mice expressing the ND4 R340H mutant [53, 76] , providing support for progression of ND4-based therapeutics for LHON towards clinical trial. In a recent study, inclusion of an MTS from the gene encoding mitochondrial cytochrome oxidase subunit 8 into the viral protein 2 (VP2) region of the AAV2 capsid directed delivery of the AAV cargo, the ND4 gene, to the mitochondrial compartment; however, the mode of action of this targeted delivery remains elusive [76] .
An alternative gene therapy being considered for LHON utilises a trans-kingdom strategy using a single subunit nuclear-encoded complex I equivalent (the NDI1 gene) from yeast, the advantage being that it circumvents both the genetic heterogeneity underlying complex I-related LHON and the barrier of delivery to mitochondria. The NDI1 gene delivered using an AAV5 vector when stereotactically injected into the superior colliculus of the brain provided benefit in a rat model of LHON [77] . Recently, intravitreally injected AAV2/5 expressing NDI1 has been shown to provide significant benefit in a murine model of LHON [78] , representing an important step forward because intravitreal viral administration is more translatable to the clinic.
Another avenue for treating mitochondrial disorders makes use of the observation that phenotypic expression of a mitochondrial disease can be influenced by levels of heteroplasmy [31] ; hence, modulation of mutant:wild type mtDNA ratios may ameliorate disease symptoms. Ratio modulation can be achieved by targeted destruction of the mutant mtDNA [79] , metabolically induced heteroplasmic shifting [40] (as observed in mutant cybrids grown in a low glucose regime), or delivery of wild type mtDNA genomes [42] . Systemic administration in neonatal mice carrying two neutral mtDNA variants of an AAV9 vector with the ApaLI restriction endonuclease engineered with a MTS to cleave one of the mtDNA variants resulted in heteroplasmic shifting in all striated muscles evaluated and demonstrated the utility of the approach to alter ratios of mtDNA variants [79] . Most recently, using what is termed an 'antigenomic' approach (which relies on complementary sequences), heteroplasmic shifting was achieved in cybrids by targeting oligoribonucleotides complementary to the boundaries of a large mtDNA deletion implicated in KSS, thereby preferentially preventing replication of the mutant mtDNA and resulting in a shift in wild type:mutant mtDNA ratios [14] . For some mitochondrial disorders, including LHON, mtDNA mutations are often homoplasmic, making such an approach inappropriate. As outlined above, delivery of wild type mtDNA also represents a rational therapeutic strategy being pursued [44] and may be used to modulate levels of heteroplasmy.
Various neurotrophic factors and antioxidants are being explored as therapies for neurodegenerative disorders, including LHON [80] . EPI-743, a small molecule whose mode of action may involve regulation of metabolic control, antioxidants effects, and or modulation of programmed cell death, is also being evaluated for LHON [81] . Idebenone, a coenzyme Q10 analogue (Santhera), is in a Phase III trial for LHON [82] . Although the beneficial effects thus far may be modest, to patients with LHON and the resulting devastating vision loss, they are welcome.
Unlike nuclear disorders, germline gene therapy is being considered for mitochondrial disorders and, indeed, significant strides have been made recently, with reports indicating that successful transfer of the nuclear genetic material from human oocytes carrying mutant mtDNA to enucleated recipient oocytes containing wild type mitochondrial genomes has been achieved [83, 84] (Figure 2 ). Of note, in previous studies, genome exchange between oocytes of nonhuman primates resulted in production of healthy offspring [85] and pronuclear transfer between fertilised human zygotes had been achieved [86] . This approach, once further developed, may allow females carrying mtDNA mutations to produce healthy offspring. Mitochondrial dysfunction is also involved in many sporadic cases of disease and tends to be characterised by an accumulation of mutant mtDNA throughout the lifetime of the individual. For such diseases, somatic gene therapy strategies rather than germline strategies will remain the focus.
Concluding remarks
Perturbations in mitochondrial function play a role in a wide array of diseases, providing enormous impetus to the scientific community to develop methods to treat or circumvent these conditions. Efficient delivery of nucleotide and peptide-based drugs to mitochondria represents a key objective, but is not trivial given the double-membrane structure of this organelle and the thousands of mitochondrial genomes resident in each cell. Many endogenous mitochondrial import pathways are being harnessed to aid drug delivery, and there have been some early successes with these approaches, although much remains to be done. Further exploration of the mitochondrial transcriptome and proteome should uncover additional pathways for import and expedite the future development of efficient delivery strategies. Although the rationale for treatment of symptomatic patients is obvious, the prophylactic use of future therapies in pre-symptomatic patients will need to be explored in the context of each emerging therapy and associated risks and benefits. Unlike gene therapies for disorders with a nuclear origin that thus far have been limited to somatic approaches, both somatic and germline strategies are being considered for mitochondrial diseases, as detailed above. Although further advances will be required in all of these areas, the stage is now set for an explosion in the development and evaluation of novel therapies targeting the mitochondrial deficiencies characteristic of so many human disorders.
